It has been proposed that complex regional pain syndrome (CRPS) is a posttraumatic autoimmune disease, and we previously observed that B cells are required for the full expression of CRPS-like changes in a mouse tibia fracture CRPS model. The current study used the mouse model to evaluate the progression of postfracture CRPS-like changes in wild-type (WT) and muMT fracture mice lacking B cells and antibodies. The pronociceptive effects of injecting WT fracture mouse serum antibodies into muMT fracture mice were also evaluated. Postfracture pain behaviors transitioned from being initially dependent on both innate and autoimmune inflammatory mechanisms at 3 weeks after fracture to being entirely mediated by antibody responses at 12 weeks after fracture and spontaneously resolving by 21 weeks after fracture. Furthermore, serum IgM antibodies from WT fracture mice had pronociceptive effects in the fracture limb when injected into muMT fracture mice. IgM antibody levels gradually increased in the fracture limb hind paw skin, sciatic nerve, and corresponding lumbar cord, peaking at 12 to 18 weeks after fracture and then declining. Immunohistochemistry localized postfracture IgM antibody binding to antigens in the fracture limb hind paw dermal cell nuclei. We postulate that fracture induces expression of neoantigens in the fracture limb skin, sciatic nerve, and cord, which trigger B cells to secret IgM antibodies that bind those antigens and initiate a pronociceptive antibody response. Autoimmunity plays a key role in the progression of nociceptive and vascular changes in the mouse fracture model and potentially contributes to the CRPS disease process.
Introduction
Complex regional pain syndrome (CRPS) usually develops after a regional injury and presents with distal limb nociceptive, vascular, and bone changes that exceed the expected clinical course of the inciting injury in both magnitude and duration, frequently resulting in significant motor impairment and disability. 46 Improving our understanding of the mechanisms supporting CRPS may help us to understand the temporal progression of the condition's manifestations and suggest new avenues to treatment. The study of both the innate and adaptive systems of immunity in patients and in animal models may move us closer to those goals.
Population-based studies indicate that distal limb fracture is the most common cause of CRPS, 9, 40 and we have developed a tibia fracture rodent model closely resembling CRPS. Distal tibia fractured rats and mice casted for 3 to 4 weeks develop hind paw allodynia, unweighting, warmth, edema, increased spontaneous protein extravasation, and regional periarticular bone loss. 17 The fracture CRPS model has been used successfully to study the effects of fracture on neuropeptide signaling, 17, 19, 51, 53 the sympathetic nervous system, 28 mast cell infiltration, 33 keratinocyte 44, 51, 54 and microglia 34, 43 inflammatory mediator (IL-1, IL-6, tumor necrosis factor (TNF), CCL2, and nerve growth factor) production, 14, 30, 32, 38, 39, 52 and other CRPS-related phenomena. 18 We recently used the fracture model to investigate the effects of B-cell depletion using anti-CD20 antibodies or B-cell deficient muMT mice. 29 We observed that (1) wild-type (WT) mice treated with intravenous (i.v.) anti-CD20 antibody had virtually no mature B cells and exhibited attenuated hind paw allodynia, unweighting, warmth, and edema; (2) muMT mice lacking B cells and IgM had attenuated nociceptive and inflammatory changes at 3 weeks after fracture; (3) i.v. anti-CD20 treatment did not prevent the upregulation of cutaneous inflammatory mediators at 3 weeks after fracture in WT mice; (4) IgM-containing immune complexes were deposited in the skin and sciatic nerve at 3 weeks after fracture in WT mice but not in muMT fracture mice; and (5) complement system membrane attack complex deposition in the skin and sciatic nerve after fracture was partially reversed by anti-CD20 treatment. Collectively, these results suggest that autoimmunity partially contributes to development of nociceptive changes and is crucial for the development of vascular changes in the mouse fracture CRPS model.
Based on these experiments, we postulated that fracture can induce the regional expression of novel antigens in the fracture limb hind paw skin and sciatic nerve, subsequently triggering B cells to secret autoantibodies capable of binding to those antigens and initiating a regionally restricted antibody-antigencomplement response resulting in complement sensitization of Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
nociceptive neurons. 23 The current study tested the hypothesis that serum antibodies from fracture mice can induce regionally restricted pain behaviors in B-cell deficient fracture mice and proceeded to identify the immunoglobulin isotype responsible for these pronociceptive effects. Additional experiments tested the hypothesis that in the first 12 weeks after fracture, the hind paw pain behaviors are dependent on both innate and autoimmune inflammatory mechanisms, but after 3 months, the hind paw keratinocyte, mast cell, and microglia-mediated innate inflammation resolves and the residual chronic pain behavior is primarily mediated by autoantibody responses.
Materials and methods

Animals
These experiments were approved by the Veterans Affairs Palo Alto Health Care System Institutional Animal Care and Use Committee (Palo Alto, CA) and followed the animal subjects' guidelines of the International Association for the Study of Pain. Three-month-old male C57BL/6J mice (#000664; Jackson Laboratory, Bar Harbor, ME) were designated the WT mice and muMT mice lacking mature B cells and immunoglobulin, on a C57BL/6J congenic background (#002288; Jackson Laboratory, Bar Harbor, ME) were used in these experiments. The animals were housed 4 per group under pathogen-free conditions with soft bedding and were given food and water ad libitum, with a 12:12 light:dark cycle. During the experimental period, the animals were fed Teklad lab rodent diet 2018 (Harlan Laboratories, Indianapolis, IN), which contains 1.0% calcium, 0.7% phosphorus, and 1.5 IU/g vitamin D3, and were kept under standard conditions with a 12-hour light-dark cycle. Data collection was conducted blind to group assignment.
Surgery
The fracture model was performed in 3-month-old male mice as previously described. 19 Under isoflurane anesthesia, a hemostat was used to make a closed fracture of the right tibia just distal to the middle of the tibia. The hind limb was then wrapped in casting tape (Delta-Lite; BSN Medical, Hamburg, Germany), so the hip, knee, and ankle were all fixed. After fracture and casting, the mice were given subcutaneously 2 days of buprenorphine (0.05 mg/ kg) and enrofloxacin (5 mg/kg) as well as 1.0 mL of normal saline. At 3 weeks after surgery, the mice were anesthetized with isoflurane and the cast removed. All mice had union at the fracture site by manual inspection.
Hind paw nociceptive testing
Mechanical allodynia was assayed using nylon von Frey filaments according to the "up-down" algorithm as previously described. 7 The mice were placed on wire mesh platforms in clear cylindrical plastic enclosures 10 cm in diameter and 40 cm in height, and after 15 minutes of acclimation, von Frey fibers of sequentially increasing stiffness were applied against the hind paw plantar skin at approximately midsole, taking care to avoid the tori pads, and pressed upward to cause a slight bend in the fiber and left in place for 5 seconds. Withdrawal of or licking the hind paw after fiber application was scored as a response. When no response was obtained, the next stiffest fiber in the series was applied to the same paw; if a response was obtained, a less stiff fiber was applied. Testing proceeded in this manner until 4 fibers had been applied after "negative 1 positive or positive 1 negative" response. Hind paw testing was performed bilaterally. Estimation of the mechanical withdrawal threshold by data-fitting algorithm permitted the use of parametric statistics for analysis. 37 These data were analyzed as the difference between the fracture side and the contralateral-untreated side, thus a negative value represents a reduction in the fracture hind paw withdrawal threshold.
An incapacitance device (IITC Life Science, Woodland Hills, CA) was used to measure bilateral hind paw weightbearing. The mice were manually held in a vertical position over the apparatus with the hind paws resting on separate metal scale plates, and the entire weight of the mouse was supported on the hind paws. The duration of each measurement was 6 seconds, and 6 consecutive measurements were taken at 10-second intervals. All 6 readings were averaged to calculate the bilateral hind paw weight-bearing values. Right hind paw (fracture side) weightbearing data were analyzed as a ratio between the right hind paw weight and the average of right and left hind paw values {[2R/(R 1 L)] 3 100%}, thus a value less than 100% represents a decrease in weightbearing in the fracture limb.
Hind paw temperature testing
The temperature of the bilateral hind paws was measured using a fine-wire thermocouple (Omega Engineering, Norwalk, CT) applied to the paw skin, as described previously. 30 The investigator held the wire using an insulating Styrofoam block. Three sites were tested over the dorsum of the hind paw: the space between the first and second metatarsals (medial), the second and third metatarsals (central), and the fourth and fifth metatarsals (lateral). After a site was tested in 1 hind paw, the same site was immediately tested in the contralateral hind paw. The testing protocol was medial dorsum right then left, central dorsum right then left, lateral dorsum right then left, medial dorsum left then right, central dorsum left then right, and lateral dorsum left then right. The 6 measurements for each hind paw were averaged for the mean temperature. These data were analyzed as the difference between the fracture side and the contralateral untreated side, thus a positive value represents increased temperature in the fracture paw.
Hind paw thickness testing
A laser sensor technique was used to determine the dorsalventral thickness of the bilateral hind paws, as we have previously described. 30 For laser measurements, each rat was briefly anesthetized with isoflurane and then held vertically so the hind paw rested on a table top below the laser. The paw was gently held flat on the table with a small metal rod applied to the top of the ankle joint. Using optical triangulation, a laser with a distancemeasuring sensor was used to determine the distance to the table top and to the top of the hind paw at the midpoint of the third metatarsal and the difference was used to calculate the dorsalventral paw thickness. The measurement sensor device used in these experiments (Limab, Goteborg, Sweden) has a measurement range of 200 mm with a 0.01-mm resolution. These data were analyzed as the difference between the fracture side and the contralateral-untreated side, thus a positive value represents increased paw thickness in the fracture paw. (Fig. 1) . Wild-type (n 5 12) and muMT mice (n 5 11) underwent baseline behavioral testing (measuring hind paw von Frey allodynia, unweighting, warmth, and edema) and then, under isoflurane anesthesia, the distal tibia was fractured and casted. The cast was removed after 3 weeks of hind limb immobilization, and behavioral testing was repeated the next day. Additional behavioral testing was performed at 7, 10, 12, 15, 18, and 21 weeks after fracture. Another cohort of WT fracture mice were injected at 12 weeks after fracture with anti-mouse CD20 antibody (200 mg/100 mL, i.v., Genentech, South San Francisco, CA, n 5 10) or vehicle (n 5 10). Previously, we demonstrated that CD20 antibody treatment completely eliminated CD2201 B cells in the blood and spleen for 2 weeks after injection, and that fracture muMT mice lacking B cells had no IgM deposition in the fracture hind paw skin or sciatic nerve. 29 Hind paw nociceptive testing (von Frey allodynia and unweighting) was performed before injection and at 1, 7, 14, 21, and 28 days after injection.
2.7. Serum and immunoglobulin injection experiments in the fracture mouse complex regional pain syndrome model This experiment examined the pronociceptive (hind paw mechanical allodynia and unweighting) and inflammatory (hind paw warmth and edema) effects of 3-week postfracture WT mouse serum when injected into 3-week postfracture WT and muMT mice (Fig. 2) . Blood was collected by transcardial puncture in isoflurane anesthetized 3-week postfracture WT mice. The blood was left undisturbed at room temperature for 60 minutes to allow clotting, then the blood samples were centrifuged at 1,500g for 15 minutes at 4˚C and the serum supernatants were aliquoted and frozen at 280˚C. Wild-type (n 5 7) and muMT mice (n 5 8) underwent baseline behavioral testing (measuring hind paw von Frey allodynia, unweighting, warmth, and edema) and then, under isoflurane anesthesia, the distal tibia was fractured and casted. At 3 weeks after fracture, the casts were removed and behavioral testing was repeated the next day and then the mice were injected with the 3 weeks after fracture WT mouse serum (500 mL, intraperitoneal [i.p.]). Further behavioral testing was performed at 1, 7, 14, and 21 days after injection. Additional muMT mice (n 5 10) underwent tibia fracture and casting, and behavioral testing was performed at baseline and 3 weeks after fracture, then the mice were injected with serum (500 mL, i.p.) from nonfractured WT control mice and behavioral testing was repeated at 1, 7, 14, and 21 days after serum injection.
In another experiment, serum was collected from 3, 18, and 21 weeks after fracture WT mice and from nonfractured control WT mice and the serum was injected into 3-week postfracture muMT mice (Fig. 3) . The muMT mice underwent baseline nociceptive behavioral testing (measuring hind paw von Frey allodynia and unweighting), and then, under isoflurane anesthesia, the distal tibia was fractured and casted. At 3 weeks after fracture, the casts were removed and the next day nociceptive behavioral testing was repeated and the mice were injected with either 3-(n 5 10), 18-(n 5 10), 21-(n 5 6) week postfracture WT mouse serum (500 mL, i.p.) or serum from nonfracture control WT mice (n 5 8). Further nociceptive behavioral testing was performed at 1, 7, 14, and 21 days after injection.
An additional experiment tested the pronociceptive effects of 3-week postfracture WT mouse serum in 21-week and 29-week postfracture WT mice with resolved allodynia and unweighting (Fig. 4) . The WT fracture mice underwent baseline nociceptive behavioral testing (measuring hind paw von Frey allodynia and unweighting) at 21 (n 5 8/group) or 29 (n 5 8/group) weeks after fracture, and then mice were injected with either 3-week postfracture WT mouse serum (500 mL, i.p.) or serum from nonfracture control WT mice. Further nociceptive behavioral testing was performed at 1, 5, 7, 9, 14, and 21 days after injection.
Another experiment was designed to identify the immunoglobulin isotype responsible for the pronociceptive effects of 3-week postfracture WT serum in 3-week postfracture muMT mice (Fig. 5) . Under isoflurane anesthesia, transcardial puncture was performed in 3-week postfracture WT mice and the serum was collected. The IgM from serum was extracted with a polypropylene column (BioRad, Hercules, CA), which was prepacked with CaptureSelect IgM Affinity Matrix (Life Technologies, Carlsbad, CA) and a Slide-A-Lyzer Dialysis Cassettes (10K MWCO; Life Technologies). The bound IgM was eluted using 100-mM glycine pH 3, the pH was adjusted to 7.4 using 1M Tris pH 8.0, and a Slide-A-Lyzer Dialysis Cassettes (10K MWCO; Life Technologies) was used to remove glycine from protein, and then quantified using a NanoDrop ND-1000 UV-Vis spectrophotometer (NanoDrop Technologies, Wilmington, DE). The recovery rate was 228 mg IgM/mL serum, which is virtually identical to the 220 mg IgM/mL serum concentration previously reported for C57BL/6 mice. 25 The dose of IgM used in the current study (500 mg, i.p.) was 4.4 fold greater than the amount of IgM that would be predicted in 500 mL of mouse serum (the volume of serum used in the injection studies described in Figs. 2-4) . The IgG from serum was extracted with CaptureSelect IgG Affinity Matrix (Life Technologies), the pH was adjusted to 7.4 using 1M Tris pH 8.0, and a Slide-A-Lyzer Dialysis Cassettes (10K MWCO; Life Technologies) was used to remove glycine from protein, and quantified using a NanoDrop ND-1000 UV-Vis spectrophotometer (NanoDrop Technologies). The recovery rate was 1.2 mg IgG/mL serum, which is approximately half the 2.4 mg IgG/mL serum concentration reported for C57BL/6 mice. 25 The dose of IgG used in the current study (3.6 mg, i.p.) was 3 fold greater than the amount of IgG that would be predicted in 500 mL of WT fracture mouse serum. Previous investigators have used much lower doses of IgG (120 mg/ mouse) antibody to evoke autoimmune responses in mice, 49 ,56 thus we were confident that a negative response to 3.6 mg of fracture mouse IgG would be physiologic and not attributable to insufficient dosage.
To test the pronociceptive effects of the immunoglobulin isotypes, muMT mice underwent baseline nociceptive behavioral testing (measuring hind paw von Frey allodynia and unweighting), and then, under isoflurane anesthesia, the distal tibia was fractured and casted. At 3 weeks after fracture, the casts were removed and the next day nociceptive behavioral testing was repeated and the mice were injected with either IgM (500 mg, i.p., n 5 11) or IgG (3.6 mg, i.p., n 5 11) from 3-week postfracture WT mice or serum (500 mL, i.p.) from nonfracture control WT mice (n 5 11). Further nociceptive behavioral testing was performed at 1, 7, 14, and 21 days after injection.
Enzyme immunoassay for albumin, IgM, and IgG
At 3 weeks after fracture, WT mice were euthanized and the fracture limb hind paw skin, sciatic nerve, and corresponding L4,5 lumbar spinal cord tissues were collected and frozen immediately on dry ice (n 5 9). Control tissues were collected from nonfractured WT mice (n 5 11). Samples were cut into fine pieces in ice-cold phosphate buffered saline, pH 7.4, containing a cocktail of protease inhibitors (Roche Applied Science, Indianapolis, IN) and followed by homogenization using a Polytron device (Brinkmann Instruments, Westbury, NY). Homogenates were centrifuged at 12,000g for 15 minutes at 4˚C, and supernatant fractions were frozen at 280˚C until required for enzyme-linked immunospecific assay (ELISA) performance. An aliquot was subjected to protein assay (Bio-Rad, Hercules, CA) to normalize mediator levels. Albumin, IgM, and IgG protein levels were determined by using ELISA kits (GenWay Biotech, San Diego, CA) according to the manufacturer's instructions. The results of these assays were confirmed by repeating each experiment twice (Fig. 6) . Another ELISA study examined IgM protein levels in the fracture limb hind paw skin and sciatic nerve collected from 3-, 7-, 12-, 18-, 21-, 23-week postfracture WT mice and nonfracture WT controls (Figs. 7A and B, n 5 8/group).
Western blot analysis for IgM
The L4-5 lumbar spinal cords ipsilateral to the fracture limb were harvested from 3-, 7-, 12-, 18-, and 21-week postfracture WT mice and nonfracture WT controls (n 5 4/group) and processed IgM injection had no effect on nociceptive testing in the contralateral hind paw (data not shown). IgG (5.0 mg, i.p.) injection had no effect. A 2-way repeated-measures analysis of variance was performed followed by a Holm-Sidak test for post hoc contrasts. Data are expressed as mean values 6 SEM. #P , 0.05 and ##P , 0.01 for muMT-FX 1 WT-FX IgM (n 5 9-11) vs muMT-FX 1 no FX-WT serum (n 5 9-11) or muMT-FX 1 WT-FX IgG (n 5 9-11). muMT, mice lacking B cells; FX, fracture; BL, baseline; 3-wk FX, 3-week post-FX. Figure 6 . IgM protein levels were elevated in the hind paw skin and sciatic nerve at 3-week postfracture (FX) in the wild-type (WT) mice. Enzyme immunoassays were used to measure albumin, IgM, and IgG protein levels in the FX limb hind paw skin, sciatic nerve, and corresponding lumbar spinal cord. Compared with tissues collected from control nonfractured WT mice, both albumin (A) and IgM (B) protein levels were increased in the hind paw skin and sciatic nerve after FX, but not in the spinal cord. Control mouse IgG (C) protein levels were almost 80 and 40 fold greater in the skin and sciatic nerve than IgM levels, but were unchanged after FX. Spinal cord levels of albumin, IgM, and IgG were extremely low. A 1-way analysis of variance was performed followed by a Holm-Sidak test for post hoc contrasts. Data are expressed as mean values 6 SEM. *P , 0.05, **P , 0.01, and ***P , 0.001 FX (n 5 7-8) vs Control (n 5 7-8). Control, nonfractured WT mice; FX, 3-week postfracture WT mice; Skin, hind paw skin in the FX limb; Sciatic, sciatic nerve in the FX limb; Cord, lumbar spinal cord corresponding to the FX limb. for IgM and b-actin Western blot analyses, as we have previously described. 29 IgM/actin band intensity ratio was calculated to demonstrate the changes in spinal IgM levels at various timepoints after fracture (Fig. 7C) .
Tissue processing and immunofluorescence confocal microscopy
This experiment was performed to identify the cellular localization of IgM autoantibody immunostaining in the fracture limb hind paw skin (Fig. 8) . Three-week postfracture WT mice were euthanized and immediately perfused with 4% paraformaldehyde in phosphatebuffered saline (PBS), pH 7.4, through the ascending aorta and the hind paw skin including subdermal layers was removed and postfixed in 4% paraformaldehyde for 2 hours, and then the tissues were treated with 30% sucrose in PBS at 4˚C before embedding in optical coherence tomography (Sakura Finetek, Torrance, CA). After embedding, 10-mm thick slices were made using a cryostat, mounted onto Superfrost microscope slides (Fisher Scientific, Pittsburg, PA), and stored at 280˚C.
Under isoflurane anesthesia, transcardial puncture was performed in 3-week postfracture WT mice and the serum was collected. The IgM from the serum was extracted with polypropylene column (BioRad) which was prepacked with CaptureSelect IgM Affinity Matrix (Life Technologies), and a Slide-A-Lyzer Dialysis Cassettes (10K MWCO; Life Technologies) was used to remove glycine from protein and quantified using a NanoDrop ND-1000 UV-Vis spectrophotometer (NanoDrop Technologies). IgM labeling was performed using Alexa Fluor 488 NHS Ester (Life Technologies) with the dye-IgM molar ratio at 50:1 under pH 7. The free dye was removed with a Slide-A-Lyzer Dialysis Cassettes (10K MWCO; Life Technologies). Hind paw skin sections from control and 3-week postfracture mice were incubated with IgM-488 at 1:500 dilution overnight at 4˚C in PBS pH 7. After 3 washes, the sections were mounted with antifade mounting medium (Invitrogen). Images were visualized and captured using a confocal microscope (Zeiss LSM710 Upright multiple photon; Carl Zeiss, Jena, Germany). Control experiments included incubation of slices in primary and secondary antibody-free solutions, both of which led to low-intensity nonspecific staining patterns in preliminary experiments (data not shown).
Statistical analysis
Statistical analysis was performed using a 2-way repeatedmeasures analysis of variance (Figs. 1-5 ) or a 1-way analysis of variance (Figs. 6 and 7) with Holm-Sidak multiple comparisons test for post hoc contrasts. All data are presented as the mean 6 SEM, and differences are considered significant at a P value less than 0.05 (Prism 5; GraphPad Software, San Diego, CA). Figure 1 illustrates that at 3 weeks after fracture, WT mice exhibited unilateral hind paw von Frey allodynia (A), unweighting (B), warmth (E), and edema (F). The muMT fracture mice lacking mature B cells and immunoglobulin also exhibited 3-week postfracture hind paw allodynia and unweighting, but to a lesser extent than the WT fracture mice, and failed to develop hind paw warmth or edema. Hind paw allodynia and unweighting pain behaviors resolved slowly over time, with muMT fracture mice resolving by 12 weeks after fracture, and WT fracture mice resolving by 21 weeks after fracture. Hind paw warmth and edema resolve by 7 weeks after fracture in the WT fracture mice. When anti-CD20 antibody (200 mg/100 mL, i.v.) was injected into 12-week postfracture WT mice, it completely reversed allodynia and unweighting within 7 days and this effect persisted for 21 days after injection. We had previously demonstrated that this dose of anti-CD antibody completely depleted mature B cells in WT mice and partially reversed allodynia and unweighting in 3-week postfracture WT mice. 29 Collectively, these data suggest that at 3 weeks after fracture, mature B cells are partially responsible for the hind paw allodynia and unweighting observed in the WT fracture mice, but by 12 weeks after fracture, a switch occurred in the nociceptive mechanisms contributing to hind paw allodynia and unweighting, with B cells becoming entirely responsible for the hind paw nociceptive behaviors. Changes in IgM levels in the ipsilateral hind paw skin, sciatic nerve, and lumbar spinal cord at 3, 7, 12, 18, 21, and 23 weeks after fracture (FX) in wild-type (WT) mice. IgM levels were determined by enzyme immunoassay in the skin (A) and sciatic nerve (B) and by Western blot analysis in spinal cord (C), because of the low IgM levels observed in the spinal cord. After fracture, there was a gradual increase in IgM levels in the hind paw skin (A), sciatic nerve (B), and spinal cord (C), peaking at between 12 and 18 weeks postfracture and then declining to control levels by 23 weeks after fracture. Data were analyzed using a 1-way analysis of variance followed by a Holm-Sidak test for post hoc contrasts, error bars indicate SEM. *P , 0.05, **P , 0.01, and ***P , 0.001 for fracture (FX, n 5 4-8) vs control (n 5 4-8). Control, nonfracture WT mice; FX, fracture WT mice; FX (week), weeks after fracture.
Results
Postfracture nociceptive and vascular changes in wild-type and B-cell deficient muMT mice
Serum from wild-type fracture mice had pronociceptive effects in muMT mice
When serum from 3-week postfracture WT mice was injected into 3-week postfracture muMT mice, the mice gradually developed increased hind paw von Frey allodynia and unweighting over the ensuing week and, consistent with the half-life of immunoglobulin, these pronociceptive effects resolved by 2 weeks after injection (Fig. 2) . The pronociceptive effects of the serum were restricted to the fracture limb and were not observed in nonfractured mice (data not shown). When 3-week postfracture WT mouse serum was injected into 3-week postfracture WT fracture mice, there was no effect on hind paw allodynia, unweighting, warmth, or edema. These data suggest that fracture-induced autoantibodies in the serum of WT fracture mice have pronociceptive effects that are regionally restricted to the fracture hind paw and not observed in control nonfracture WT mice. When WT fracture serum is injected into muMT fracture mice lacking mature B cells and immunoglobulin, there is an additional sensitizing effect on hind paw allodynia and unweighting, but when WT fracture serum is injected into WT fracture mice, there is no further sensitizing effect on the hind paw allodynia and unweighting because WT fracture mice already express these pronociceptive autoantibodies.
3.3. The pronociceptive effects of wild-type fracture mouse serum resolved by 21 weeks after fracture When 3-week postfracture muMT mice were injected with serum from 3-and 18-week postfracture WT mice, it caused a gradual increase in hind paw allodynia and unweighting, but 21-week postfracture serum had no pronociceptive effects (Fig. 3) . These results support the hypothesis that the resolution of hind paw allodynia and unweighting at 21 weeks after fracture in the WT mice (Fig. 1) is due to the loss of pronociceptive autoantibodies at 21 weeks after fracture.
3.4. Serum from 3-week postfracture wild-type mice was pronociceptive when injected into 21-and 29-week postfracture wild-type mice Wild-type fracture mice had no hind paw allodynia or unweighting at 21 and 29 weeks after fracture, but hind paw allodynia and unweighting were rekindled when these mice were injected with serum from 3-week postfracture WT mice (Fig. 4) . Injection of 3-week postfracture WT serum had no effect on nociceptive testing in the contralateral intact limb in the 21-and 29-week postfracture mice. These results suggest that pronociceptive autoantibodies are no longer being expressed in the 21-and 29-week postfracture WT mice, but that these mice do continue to express fracture hind limb restricted unique antigens that the pronociceptive autoantibodies must bind with to activate antigen-autoantibody-complement complexes capable of inducing nociceptive sensitization. Injecting purified IgM from 3-week postfracture WT mice into 3-week postfracture muMT mice had the same pronociceptive effects as serum injection (Fig. 5) . IgM injection had no effect on nociceptive testing in the contralateral intact limb in the 3-week postfracture muMT mice. Injection of purified IgG from 3-week postfracture WT mice into 3-week postfracture muMT mice had no nociceptive effects, and serum from nonfractured WT mice had no effect in the muMT fracture mice. These results indicate that IgM is the immunoglobulin isotype responsible for postfracture autoantibody-mediated pronociceptive effects.
3.6. IgM protein levels were elevated in the fracture limb hind paw skin and sciatic nerve
To detect whether the immunoglobulin isotypes indicative of autoimmunity could be found in the fracture limb hind paw skin, sciatic nerve, and corresponding L4/5 lumbar spinal cord tissue, ELISA assays were used to analyze albumin, IgM, and IgG protein levels in nonfracture controls and 3-week postfracture WT mice. Compared with nonfracture control tissues, both albumin and IgM levels were increased in the fracture limb hind paw skin and sciatic nerve, but not in the corresponding lumbar spinal cord (Fig. 6) . IgG levels were unchanged after fracture. Spinal cord levels of albumin, IgM, and IgG were extremely low. Collectively, these results suggest that only IgM immune complexes are present in the skin and sciatic nerve at 3 weeks after fracture in WT mice.
3.7. Postfracture temporal changes in IgM protein levels in the hind paw skin, sciatic nerve, and spinal cord
The pronociceptive effects of fracture WT mouse serum in postfracture muMT mice were mediated by IgM antibodies (Fig.  5 ) and were present only in serum collected between 3 and 18 weeks after fracture (Fig. 3) . These pronociceptive effects were not observed with serum collected from 21-week postfracture WT mice (Fig. 3) , suggesting that IgM autoantibodies continued to be generated for up to 18 weeks after fracture. To test this hypothesis, IgM levels were measured in the fracture limb hind paw skin and sciatic nerve by ELISA, and in corresponding L4/5 lumbar spinal cord by Western blot assay, at 0, 3, 7, 12, 18, 21, and 23 weeks after fracture in WT mice. Western blot assay was used for spinal cord tissues because of the extremely low levels of IgM present in spinal cord tissue and the greater sensitivity of the Western assay, relative to ELISA. IgM levels began increasing at 3 weeks, peaked between 12 and 18 weeks, and began declining after that, reaching control levels by 23 weeks after fracture (Fig.  7) . These results support the hypothesis that IgM autoantibodies are expressed for 18 weeks after fracture, consistent with the duration of postfracture nociceptive sensitization.
IgM autoantibody-antigen binding in the fracture hind paw skin was localized to dermal nuclei
Immunohistochemistry was used to identify the cellular location of IgM autoantibody-antigen binding in the fracture hind paw skin of WT mice. IgM antibody purified from 3-week fracture WT mice was labeled with a fluorescent marker and used to immunostain antigens in hind paw skin sections from 3-week fracture WT mice. 49,6-diamidino-2-phenylindole (DAPI) counter staining was used to identify cell nuclei. IgM immunostaining was diffusely distributed throughout the dermal cell nuclei in the fracture limb hind paw skin, but only minimal staining was observed in the contralateral hind paw skin sections and in nonfracture control hind paw skin sections (Fig. 8) . These results support the hypothesis that fracture can induce the regional expression of dermal nuclear antigens in the fracture limb hind paw skin, subsequently triggering B cells to secret IgM autoantibodies capable of binding to those nuclear antigens and initiating an antibody response.
Discussion
Evidence from patients and animal models suggest that both sensory c-fibers and sympathetic neurons function aberrantly in CRPS. 5, 35, 53 Additional studies measuring interleukin 6 (IL-6), tumor necrosis factor alpha (TNF), and other pronociceptive mediators associated with the innate system of immunity, have demonstrated that these mediators are elevated in the skin blister fluid of patients with CRPS, 16, 20, 36 as is tryptase, a marker for mast cells capable of releasing a host of nociceptive mediators. 22 Using the CRPS fracture model, we have shown that facilitated release of neuropeptides such as substance P and calcitonin gene-related peptide from sensory c-fibers, 53 as well as norepinephrine released from sympathetic nerve terminals, lead to inflammation and pain sensitization by the activation of neuropeptide and adrenergic receptors on the surface of keratinocytes, vascular endothelial cells, mast cells, and microglia, causing the local production of high levels of inflammatory mediators such as interleukin 1 (IL-1), IL-6, TNF, C-C motif chemokine ligand 2 (CCL2), and nerve growth factor. 19, 28, [30] [31] [32] [33] [34] 38, 39, 43, 44 Experimental maneuvers blocking these innate immune responses only partially normalize the nociceptive and vascular changes in the CRPS fracture model. 14, 30, 33, 38, 39, 54 Similarly, CRPS clinical studies observe only partial therapeutic responses with treatments that inhibit innate immune mechanisms. 6, 21, 24, 48 Recently, we examined bilateral skin punch biopsies from 55 patients with CRPS and demonstrated unilateral keratinocyte and mast cell proliferation, epidermal thickening, and keratinocyte inflammatory cytokine expression (IL-6 and TNF) in the early (,3 month duration) CRPS-affected skin. 4 This study also found that increased keratinocyte and mast cell proliferation gradually resolved over time, despite persistent pain symptoms. These results are consistent with skin blister fluid studies indicating a gradual resolution of cutaneous inflammatory mediator (IL-6 and TNF) expression over time in the CRPS-affected skin. 55 These data support the hypothesis that posttraumatic neuropeptide signaling actives keratinocyte and mast cell-mediated innate immune responses contributing to the development, but not the maintenance of CRPS, and we postulate that adaptive immunity plays a critical role in perpetuating CRPS.
At 3 weeks after fracture, the muMT fracture mice exhibited a partial reduction in allodynia and unweighting, compared with WT fracture mice, suggesting that autoantibodies partially contribute to the nociceptive sensitization observed at the 3-week timepoint (Fig. 1) . By week 12, nociceptive sensitization had resolved in the muMT fracture mice, but the WT fracture mice had residual, albeit resolving, allodynia and unweighting that was completely reversed after an anti-CD20 injection that blocked antibody production. The differing time courses for the resolution of pain behaviors in the WT and muMT fracture mice support the hypothesis that in the first 3 months after fracture nociceptive sensitization is mediated by both innate and adaptive immune mechanisms, but that more chronic sensitization is entirely dependent on B cell-secreted IgM autoantibodies. Pain behaviors in the WT mice resolved by 21 weeks after fracture, similar to the CRPS disease process, with most patients with CRPS undergoing spontaneous symptom resolution within a year of onset. 3, 40, 41, 57 Direct support for the hypothesis that autoantibodies can trigger nociceptive sensitization was obtained by demonstrating that injection of 3-week WT fracture serum caused increased hind paw allodynia and unweighting in 3-week muMT fracture mice (Fig. 2) . Injecting fracture WT mouse serum had no effect on nociceptive thresholds in the contralateral intact hind limb of the muMT fracture mice, suggesting that circulating autoantibodies alone are insufficient to cause CRPS-like changes and that neoantigens expressed in the fracture limb are required to form the antigen-antibody complexes that initiate CRPS-like changes. In addition, no pronociceptive effects were observed when 3-week WT fracture serum was injected into WT fracture mice already expressing pronociceptive autoantibodies (Fig. 2) .
When serum from 18-week postfracture WT mice was injected into 3-week muMT fracture mice, it induced increased nociceptive behaviors, but 21-week serum had no effect, suggesting that the loss of serum autoantibodies is crucial for the resolution of pain behaviors in the 21-week WT fracture mice (Fig. 3) . Furthermore, 3-week WT fracture serum had pronociceptive effects when injected into 21-or 29-week postfracture WT mice with resolved hind paw allodynia and unweighting, consistent with the hypothesis that neoantigens are still being expressed in the fracture hind limb but that autoantibodies are no longer being produced at 21 weeks after fracture (Fig. 4) . In addition, IgM deposition in the ipsilateral hind paw skin, sciatic nerve, and lumbar cord peaked at 12 to 18 weeks after fracture and then gradually diminished over time, returning to normal levels in the sciatic nerve by 21 weeks (Fig. 7) .
Injecting purified IgM obtained from 3-week WT fracture serum into 3-week muMT fracture mice had the same pronociceptive effects as serum injection, but had no effect on nociceptive thresholds in the contralateral intact hind limb (Fig. 5) . Injection of purified IgG from 3-week WT fracture serum into 3-week muMT fracture mice had no pronociceptive effects. Furthermore, when IgM and IgG levels were measured in the fracture hind limb paw skin and sciatic nerve at 3 weeks after fracture, only IgM levels were elevated, suggesting that IgM, but not IgG, was initiating the formation of antibody-antigen-complement complexes in the hind paw skin and sciatic nerve of the fracture limb (Fig. 6) . These results support the hypothesis that IgM is the immunoglobulin isotype responsible for pronociception. The immunostaining localization of IgM-antigen complex deposition in the nuclei of the dermal hind paw skin cells is another intriguing finding (Fig. 8) . The presence of antinuclear antibodies can indicate an antibody response against self and is frequently observed in autoimmune diseases.
Witebsky's criteria for an autoimmune disease include (1) evidence of an autoimmune or inflammatory disorder from clinical clues; (2) demonstration of a specific antigen; and (3) reproduction of clinical features in recipient animals by passive transfer of pathogenic antibodies. 45 Current evidence suggests that CRPS fulfills the first criteria. Patients usually exhibit characteristics of an inflammatory disease, including localized pain, redness, swelling, and warmth. 50 Proliferation of keratinocytes and mast cells occur in the affected limb, and proinflammatory cytokines are elevated in blister fluid and skin biopsies. 4, 16, 20, 36 Small CRPS clinical trials have reported beneficial effects with anti-inflammatory medications such as corticosteroids and bisphosphonates. 6, 8, 12, 48 In addition, CRPS displays a female predominance 9 and the incidence of CRPS may be higher in patients with chronic inflammatory disorders such as asthma, 10 multiple sclerosis, 42 and rheumatoid arthritis.
2 Regarding Witebsky's second criteria requiring demonstration of a specific antigen, there is some intriguing evidence for the presence of autoantibodies in CRPS. Recently, we demonstrated that fracture mouse sera (but not control sera) bind to keratin 16, elongation factor1-alpha 1, peripherin, annexin A2, and betaenolase in the fracture mouse skin and that all these antigens are upregulated or redistributed to the cell membrane after fracture. 47 In addition, fracture mouse and CRPS patient serum showed increased antibody binding to recombinant keratin 16 protein. 47 Experiments using immunohistochemical techniques and FACS analysis have identified sympathetic nervous system neurons as targets for serum antibodies from some patients with CRPS. 13, 15, 27 Follow-up experiments using a cardiomyocyte preparation suggested that most CRPS, but not healthy patients, had autoantibodies binding to and activating M-2 muscarinic or beta 2 adrenergic receptors. 26 Furthermore, a third of patients with CRPS exhibit positive antinuclear antibody tests, a standard diagnostic test for autoimmune disease. 11 In addition, plasma exchange therapy was reported effective in reducing pain in 90% of chronic patients with CRPS. 1 Together, these results demonstrate that autoantibodies are present in some patients with CRPS, but further research is required to confirm a pronociceptive role for autoantibodies in CRPS.
Collectively, the results of the current study support the hypothesis that fracture with immobilization can induce the regionally restricted expression of dermal nuclear antigens in the fracture limb, subsequently triggering B cells to secret IgM antibodies capable of binding with those antigens and initiating a pronociceptive antibody response. The time course of this pronociceptive antibody response is limited in the mouse to 21 weeks after fracture, and a similar progression of innate and autoimmune processes may explain the spontaneous resolution of symptoms that occurs in most patients with CRPS within a year of onset. 3, 40, 41, 57 We postulate that patients with CRPS usually regain immune tolerance over time and, while still making neoantigens in the injured limb, their adaptive immune system no longer identifies these antigens as "other." An obvious concern would be that some patients fail to regain immune tolerance, resulting in chronic CRPS. Future studies looking at the pronociceptive effects of CRPS patient serum in the mouse fracture model could potentially confirm Witebsky's third criteria for autoimmune disease, evidence that passive transfer of patient autoantibodies can evoke CRPS-like changes in animals. Pursuing autoimmunity as a contributor to CRPS could identify new components of the disease process, including novel mechanisms for activation of the adaptive immunity, the posttraumatic time course of the innate and adaptive pronociceptive immune responses and discovery of new treatment approaches for this disabling condition.
